<div id="readability-page-1"><p>Anderson Hoagland &amp; Co. decreased its position in  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 19.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,767 shares of the pharmaceutical company's stock after selling 3,880 shares during the period. Anderson Hoagland &amp; Co.'s holdings in Vertex Pharmaceuticals were worth $6,175,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Vertex Pharmaceuticals</strong> alerts:</span></p></div><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>Several other institutional investors have also recently made changes to their positions in the company. United Services Automobile Association purchased a new position in shares of  Vertex Pharmaceuticals in the 1st quarter valued at about $2,933,000.  Lee Johnson Capital Management LLC purchased a new stake in shares of  Vertex Pharmaceuticals during the second quarter worth approximately $721,000.  Police &amp; Firemen s Retirement System of New Jersey raised its holdings in  Vertex Pharmaceuticals by 3.7% in the second quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company's stock valued at $17,378,000 after acquiring an additional 1,393 shares in the last quarter.  Bailard Inc. raised its holdings in  Vertex Pharmaceuticals by 0.5% in the second quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company's stock valued at $16,983,000 after acquiring an additional 200 shares in the last quarter.  Finally, SteelPeak Wealth LLC purchased a new position in  Vertex Pharmaceuticals in the second quarter worth approximately $10,059,000. Hedge funds and other institutional investors own  90.96% of the company's stock. </p><h2>Insider Activity at Vertex Pharmaceuticals</h2><p>In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the completion of the sale, the executive vice president directly owned 37,725 shares of the company's stock, valued at approximately $17,202,600. This trade represents a 27.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the company's stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total value of $28,650,425.20. Following the sale, the chairman owned 24,026 shares of the company's stock, valued at $10,792,479.20. This trade represents a 72.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 151,073 shares of company stock valued at $67,326,816. 0.20% of the stock is owned by company insiders. </p><h2>Vertex Pharmaceuticals Price Performance</h2><ul><li>Best Biotech Stocks to Buy in 2025</li></ul><p>Shares of Vertex Pharmaceuticals stock opened at $459.21 on Wednesday. The firm's fifty day simple moving average is $432.64 and its 200-day simple moving average is $425.90. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.68. The stock has a market capitalization of $116.51 billion, a price-to-earnings ratio of 32.38 and a beta of 0.32. </p><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the firm posted $4.38 EPS. Vertex Pharmaceuticals's revenue for the quarter was up 11.0% on a year-over-year basis.  Analysts anticipate that  Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year. </p><h2>Analyst Ratings Changes</h2><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p>A number of equities research analysts have commented on VRTX shares. Leerink Partners raised shares of Vertex Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and dropped their price objective for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. UBS Group raised Vertex Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Thursday, December 4th. Morgan Stanley  set a $564.00 price target on Vertex Pharmaceuticals in a research note on Friday, December 5th. Weiss Ratings  reaffirmed a &#34;hold (c+)&#34; rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Evercore ISI cut their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, September 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned  a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $498.42.</p><p><b>Check Out Our Latest Stock Report on VRTX</b></p><h2>About Vertex Pharmaceuticals</h2> (Free Report)<p>Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.  </p><p>Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.</p><h2>See Also</h2><ul><li>Five stocks we like better than Vertex Pharmaceuticals</li><li>The boring AI play that could pay up to $4,290 monthly</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Trump’s “real estate deal for America” explained</li><li>A month before the crash</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VRTX

<p>Anderson Hoagland & Co. reduced its stake in Vertex Pharmaceuticals by 19.7% in Q3, selling 3,880 shares. Insiders sold 151,073 shares worth $67.3 million. Vertex's stock opened at $459.21, with a 12-month range of $362.50-$519.68. Analysts have varied ratings, with UBS upgrading to "strong-buy" and Morgan Stanley setting a $564 target. Vertex's Q3 earnings exceeded estimates, with $3.08 billion revenue, up 11% YoY.</p>

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Anderson Hoagland & Co.